Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2024

Pharma News, 2024

Qureight secures Series A funding to accelerate drug development
Qureight secures Series A funding to accelerate drug development
UK-based data analytics startup company Qureight has secured $8.5m in a Series A funding round led by Hargreave Hale AIM VCT to accelerate drug development. The funding round attracted a consortium...
FDA halts Neumora’s schizophrenia drug trial over convulsions in rabbits
FDA halts Neumora’s schizophrenia drug trial over convulsions in rabbits
The US Food and Drug Administration (FDA) has placed a clinical hold on the Phase I trial of Neumora Therapeutics’ schizophrenia therapy, NMRA-266.
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced...
FDA approves AstraZeneca’s FASENRA for asthma in children
FDA approves AstraZeneca’s FASENRA for asthma in children
The expanded approval of FASENRA for use in younger patients comes after the regulator initially approved the therapy in 2017.
Candel wins FDA orphan drug designation for pancreatic cancer drug
Candel wins FDA orphan drug designation for pancreatic cancer drug
The US Food and Drug Administration (FDA) has granted Candel Therapeutics’ immunotherapy candidate CAN-2409 (aglatimagene besadenovec) orphan drug designation for the treatment of pa...
FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers
FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers
LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.
Vertex to expand autoimmune and inflammatory disease pipeline with $4.9bn Alpine acquisition
Vertex to expand autoimmune and inflammatory disease pipeline with $4.9bn Alpine acquisition
Vertex Pharmaceuticals has announced its acquisition of Alpine Immune Sciences, a biotechnology company focused on developing and discovering protein-based immunotherapies, in a deal worth $4.9bn.
Patient dosing continues in clinical trial of novel gene therapy for Wilson’s disease
Patient dosing continues in clinical trial of novel gene therapy for Wilson’s disease
A European clinical stage biotech company announced dosing of the first patient in cohort 2 of its ongoing phase 1/2 GATEWAY clinical trial of lead candidate VTX-801 to treat Wilson’s disease.
Most Cancer Drugs Granted Accelerated FDA Approval May Not Work
Most Cancer Drugs Granted Accelerated FDA Approval May Not Work
The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ li...
MHRA approves TMC Pharma’s Nulibry to treat rare genetic disease MoCD type A
MHRA approves TMC Pharma’s Nulibry to treat rare genetic disease MoCD type A
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved TMC Pharma’s Nulibry (fosdenopterin) to treat patients with the rare genetic disease molybdenum cofactor d...
Novartis shares positive real-world data for Leqvio in atherosclerotic CVD
Novartis shares positive real-world data for Leqvio in atherosclerotic CVD
LDL-C is a causal risk factor for ASCVD and increases the risk of heart disease and stroke. Novartis has shared new real-world data for its Leqvio (inclisiran) in reducing low-density lipoprot...
AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock
AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock
AdrenoMed AG, the vascular integrity company, today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its lead product candidate enibarcimab, a fir...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand